BACKGROUND Biodegradable polymer drug-eluting stents (BP-DES) have shown to reduce restenosis rates and have low rates of stent thrombosis. The present postmarketing surveillance assessed 1-year clinical outcomes of patients who had received NeoHexa DES in real practice. AIM To investigate 1-year clinical outcomes of Neohexa DES in real practice. METHODS Data obtained from a single-center cohort of patients who had received NeoHexa stents as part of routine treatment of coronary artery disease (CAD) were retrospectively investigated. The primary study endpoint was the rate of major adverse cardiac events (MACEs) defined as the composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) during the follow-up at 1 mo, 6 mo, and 1 year after the index procedure. RESULTS A total of 129 patients with 172 lesions were enrolled. The most common comorbid conditions were hypertension (49.61%) and diabetes mellitus (39.53%). Procedural success was achieved in all patients, and no in-hospital MACE was reported. The incidence of composite MACE at 30 d, 6 mo, and 1 year was 0.78%, 3.94%, and 4.87%, respectively. The rate of possible and probable late stent thrombosis was 0.78%. The cumulative incidences of death, MI, and TLR at 1 year were 2.44%, 0.81%, and 1.63%, respectively. CONCLUSION The relatively low rates of MACE and stent thrombosis in this study support safety and performance of NeoHexa stents, suggesting it to be an effective alternative to other contemporary stents for the treatment of de novo lesions in native coronary arteries.

Background: The importance of the right ventricle as a determinant of exercise capacity and its significant prognostic value in the evaluation of surgical outcomes has been largely proven. In this study, we sought to explore the effect of off-pump coronary artery bypass surgery (OPCAB) on right ventricular (RV) function by the different methods of RV functional assessment on transthoracic echocardiography. Materials and Methods: This is a prospective cohort study. All patients undergoing elective OPCAB were included in the study from July 1, 2016, to October 1, 2016 after an informed consent. Their preoperative, postoperative day 4, and postoperative 2-month transthoracic echocardiographic RV and left ventricular functions were evaluated and analyzed. Results: A total of 48 patients undergoing OPCAB were included in this study. The mean age of the cohort was 57.2 ± 8 years. About 85.4% (41) were males. Overall, there is a significant time effect observed in RV ejection fraction (RVEF), with a significant decline from preoperative to postoperative value and a significant increase from postoperative day 4 to postoperative 2-month value. Although RVEF was lower throughout the study in patients with events than those without events, this difference was not statistically significant. Conclusion: In this Indian cohort of patients undergoing OPCAB, there is a significant drop in RVEF, RV tissue Doppler, tricuspid annular peak systolic excursion on postoperative day 4, and also a significant increase in these values over the next 2 months though not reaching the basal value. Hence, suggesting that the drop in RV function is temporary and recovers over time in patients undergoing OPCAB. Patients with events had a lower RVEF when compared to those without events suggesting prognostication.

No abstract

No abstract

Objective: This study compared sirolimus-eluting stents (SES) with everolimus-eluting stents (EES) in coronary artery disease patients. Methods: A total of 1,174 patients were enrolled in the study; 290 patients (25.28%) were treated with EES and 884 patients (74.72%) were treated with SES. The trial (PRISM) was a randomised (in a 3:1 ratio), multicentre, single-blind, all-comers, single-arm, non-inferiority trial comparing SES and EES-implanted patients with coronary artery disease. The primary endpoint was a composite of safety parameters (including major adverse cardiac events [MACE], cardiac death, and myocardial infarction) and efficacy (parameters concerned to quantitative coronary angiogram). An intention-to-treat analysis was performed at 9 and 18-month follow-ups. Results: The baseline characteristics were similar for both EES and SES groups. At the 9-month follow-up, MACE occurred in 5.86% and 2.43% of patients in the EES and SES groups, respectively. At the 18-month follow-up, this differential remained almost the same (i.e., 5.17 % of patients treated with the EES versus 2.14% treated with the SES). The rate of definite stent thrombosis at 9-month follow-up was lower in the SES group (11 patients [1.24%]) compared to the EES group (9 patients [3.10%]). At 18-month follow-up, the rate was 2.14% (19 patients) in the SES group and 4.13% (12 patients) in the EES group. When censoring the patients at the time of stent thrombosis, no significant differences between the two stent groups were found. Conclusion: In this real-world trial, at 9 and 18-month follow-ups, SES (M’Sure-S) exhibited a better safety and efficacy profile when compared to EES in terms of MACE rates and definite stent thrombosis. However, the difference was not statistically significant and SES was found to be non-inferior to EES.